Keyword: Department of Defense
A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.
A series of “sartan” recalls has shaken consumer confidence in cheap blood pressure generics. Now the Pentagon is scrutinizing China’s production.
Here is some other vaccine news of note for the week.
Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.
BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.
Secretive Moderna shared a new peek into its infectious disease vaccines efforts Thursday.
A controversy over Sanofi's Zika vaccine candidate may spawn pricing limits for all treatments developed with the help of Defense Department funding.
Months into a bruising EpiPen pricing scandal, congressional scrutiny on Mylan continues to heat up. Top members of the Senate Judiciary Committee have called on the Federal Trade Commission to examine whether the company--already under several investigations--used anticompetitive practices to pad its revenues for its important epinephrine injector.
A University of California, Irvine, team won $8 million from the DOD's Defense Threat Reduction Agency to develop a new vaccine against Q fever.